Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 2/20 | 0.66 |
| ▸ | AKR1B1 | P15121 | 6/20 | 0.62 |
| ▸ | CA9 | Q16790 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20534434 | 1.00 | KDR (0.66) | KDRAKR1B1CA9POLBFFAR1 | |
| SCHEMBL10464668 | 0.86 | FFAR1 (0.74) | AKR1B1POLBFFAR1MEN1KMT2A | |
| SCHEMBL6885409 | 0.86 | FFAR1 (0.74) | AKR1B1POLBFFAR1MEN1KMT2A | |
| SCHEMBL6885407 | 0.86 | FFAR1 (0.74) | AKR1B1POLBFFAR1MEN1KMT2A | |
| SCHEMBL29518358 | 0.86 | FFAR1 (0.67) | KDRPOLBFFAR1MEN1KMT2A | |
| SCHEMBL21783135 | 0.82 | PPARG (0.69) | KDRMEN1KMT2AMAPT | |
| SCHEMBL28379413 | 0.82 | PPARG (0.69) | KDRMEN1KMT2AMAPT | |
| SCHEMBL29215005 | 0.82 | FFAR1 (0.79) | KDRFFAR1MEN1KMT2AMAPT | |
| SCHEMBL29215003 | 0.82 | FFAR1 (0.79) | KDRFFAR1MEN1KMT2AMAPT | |
| SCHEMBL9011343 | 0.81 | AKR1B1 (0.84) | AKR1B1CA9MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200068890-A1 | HETEROCYCLIC INHIBITORS OF LYSINE BIOSYNTHESIS VIA THE DIAMINOPIMELATE PATHWAY | LA TROBE UNIVERSITY (AU) | 2020-03-05 | — | — | US | disclosed |
| EP-3609494-A1 | HETEROCYCLIC INHIBITORS OF LYSINE BIOSYNTHESIS VIA THE DIAMINOPIMELATE PATHWAY | La Trobe University (AU) | 2020-02-19 | — | — | EP | disclosed |
| CN-110621315-A | Heterocyclic inhibitors of lysine biosynthesis via the diaminopimelic acid pathway | 拉筹伯大学 | 2019-12-27 | — | — | CN | disclosed |
| WO-2018187845-A1 | HETEROCYCLIC INHIBITORS OF LYSINE BIOSYNTHESIS VIA THE DIAMINOPIMELATE PATHWAY | LA TROBE UNIVERSITY (AU) | 2018-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200068890-A1 | HETEROCYCLIC INHIBITORS OF LYSINE BIOSYNTHESIS VIA THE DIAMINOPIMELATE PATHWAY | DDC, ODC1, DDT | KDR 4130/4885AKR1B1 225/4885CA9 2233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.